What is the Purpose of this Study?
Primary : To assess the safety and tolerability of oral BMS-986482, as monotherapy or in combination with nivolumab SC, nivolumab + relatlimab FDC SC, or bevacizumab, to establish the MTD,MAD, and/or RP2D(s) in participants with advanced solid tumor Secondary: To characterize the PK profiles of BMS-986482 and its R-/S-enantiomers BMT-792603 and BMT-792597 following oral administration as monotherapy, or in combination with nivolumab SC, nivolumab + relatlimab FDC SC, or bevacizumab, in participants with advanced solid tumors. To assess the preliminary anti-tumor effect of BMS-986482 in Part 2 as monotherapy, or in combination with nivolumab SC, nivolumab + relatlimab FDC SC, or bevacizumab, in participants with advanced solid tumors
Eligibility
- * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- * Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors